A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome
|Irritable Bowel Syndrome Colonic Diseases Diarrhea Gastrointestinal Disease||Drug: crofelemer||Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRN 002 (Crofelemer) for the Symptomatic Treatment of Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)|
- To assess the safety of TRN-002 when administered twice daily for 12 consecutive weeks.
- To assess the efficacy of TRN-002 when administered twice daily for 12 consecutive weeks.
|Study Start Date:||December 2004|
|Study Completion Date:||November 2005|
|Primary Completion Date:||November 2005 (Final data collection date for primary outcome measure)|
|Experimental: 125 mg crofelemer||Drug: crofelemer|
|Experimental: 250 mg crofelemer||Drug: crofelemer|
|Experimental: 500 mg crofelemer||Drug: crofelemer|
|Placebo Comparator: placebo||Drug: crofelemer|
The investigational drug is a natural product taken from a plant that grows in South America. The study medication will be administered orally twice a day. Subjects who are eligible to participate will have a 75% chance of receiving TRN-002 and a 25% chance of receiving placebo (a substance that looks similar to TRN 002 but has no activity). Subjects will not be able to remain on certain standard IBS medications (antidiarrheals) while participating in the study. The total duration is 16 weeks.
The study requires five study visits that include physical exams, ECG and blood draws for laboratory studies. A colon procedure (such as a colonoscopy or flexible sigmoidoscopy) may also be required if it has not been performed since your diagnosis and within the last 5 years. Participants will be asked to make daily entries into a touch-tone telephone diary on a daily basis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00101725
Show 29 Study Locations